Interventions for treating lymphocytic colitis

Chande, N; McDonald, JWD; MacDonald, JK

doi:10.1002/14651858.cd006096

Cited by 20 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a placebo-controlled trial including 41 patients, budesonide treatment was effective also in LC [95] . After 6 wk treatment, 18 of 21 patients (86%; 95% CI 65%-96%) in the budesonide group achieved a clinical response compared to eight of 20 patients (40%; 95% CI 22%-61%) in the placebo group, which yielded an odds ratio of 9.00 (95% CI 1.98-40.93; P = 0.004) [96] . The number needed to treat to achieve a clinical response with budesonide was three patients.…”

Section: Therapy and Prognosismentioning

confidence: 96%

Diagnosis and management of microscopic colitis

Tysk¹,

Bohr²,

Nyhlin³

et al. 2008

WJG

View full text Add to dashboard Cite

Microscopic colitis, comprising collagenous and lymphocytic colitis, is characterized clinically by chronic watery diarrhea, and a macroscopically normal colonic mucosa where diagnostic histopathological features are seen on microscopic examination. The annual incidence of each disorder is 4-6/100 000 inhabitants, with a peak incidence in 60-70-year-old individuals and a noticeable female predominance for collagenous colitis. The etiology is unknown. Chronic diarrhea, abdominal pain, weight loss, fatigue and fecal incontinence are common symptoms, which impair the health-related quality of life of the patient. There is an association with other autoimmune disorders such as celiac disease, diabetes mellitus, thyroid disorders and arthritis. Budesonide is the best-documented shortterm treatment, but the optimal long-term strategy needs further study. The long-term prognosis is good and the risk of complications including colonic cancer is low.

show abstract

Section: Therapy and Prognosismentioning

confidence: 96%

Diagnosis and management of microscopic colitis

Tysk¹,

Bohr²,

Nyhlin³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…9 In the treatment of MC, mesalazine has mainly been reported in retrospective studies carried out in 1996 by Bohr et al 28 and in 2004 by Olesen et al, 27 suggesting a therapeutic response in about half of patients. In 2008, Chande et al 31 conducted an uncontrolled prospective study that showed greater efficacy of mesalazine when administered over a period of 6 months. Due to the lack of control groups, the true value of the use of mesalazine when treating MC remains inconclusive.…”

Section: 2mentioning

confidence: 99%

Microscopic colitis: A literature review

Clara

Magnago

Ferreira

et al. 2016

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Microscopic colitis (MC) refers to chronic inflammation of the colon which is characterized by histologic changes at the level of a radiologically and endoscopically normal mucosa. It is a common cause of chronic non-bloody diarrhea that occurs primarily in older individuals; however, there are few studies in the literature with strong scientific evidence compared to other inflammatory bowel diseases (IBD), which limits the knowledge of physicians and pathologists. This article aims to review the information on MC, describing diagnostic methods and drugs available for treatment. We conducted a search of the Pubmed database and CAPES Portal using the keywords "microscopic colitis", "collagenous colitis", "lymphocytic colitis", and "review" for selection of articles published between 1996 and 2015 related to the topic. Based on the studies discussed in this review, we conclude that MC is a relatively new gastrointestinal disorder, most studies are incipient particularly with respect to pathophysiology and immunology, and budesonide is the best documented short-term treatment. However, further studies are needed to elucidate the best strategy for treatment in the long term.

show abstract

“…Therapies have included traditional corticosteroids, budesonide, 5-ASA compounds, azathioprine, methotrexate, cyclosporine, antibiotics, bismuth subsalicylate, cholestyramine, octreotide, ketotifen, verapamil, pentoxifylline, loperamide and dietary modifications [Chande et al 2008a[Chande et al , 2008b. Few randomized control trials have been carried out.…”

Section: Microscopic Colitismentioning

confidence: 99%

Therapeutic benefits of budesonide in gastroenterology

O’Donnell

O’Moráin

2010

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Budesonide is a synthetic steroid of the glucocorticoid family with a high topical antiinflammatory activity. Enteric-coated formulations resist gastric-acid degradation, delivering active drug to the small intestine and proximal colon. Budesonide has a high first-pass metabolism with minimal systemic absorption. It is therefore felt to cause fewer side effects than traditional glucocorticosteroids and to be generally well tolerated. The aim of this paper is to examine the utility of this medication in frequently encountered gastrointestinal conditions: Crohn's disease, ulcerative colitis, microscopic colitis and eosinophilic oesophagitis. A Medline search was performed to find published original research and review articles relating to the use budesonide in common gastroenterological conditions. The results showed that budesonide is efficacious in the induction and short-term maintenance of Crohn's disease. Budesonide is the best-documented treatment for microscopic colitis. It is well proven to be effective in the induction of remission in collagenous colitis but its use in lymphocytic colitis remains less well documented. In conclusion, budesonide is an effective glucocorticosteroid therapy for many chronic gastrointestinal diseases. In combination with its efficacy, the low incidence of serious side effects associated with this drug should keep it at the forefront in the therapeutic arsenal of any gastroenterologist.

show abstract

Interventions for treating lymphocytic colitis

Cited by 20 publications

References 0 publications

Diagnosis and management of microscopic colitis

Diagnosis and management of microscopic colitis

Microscopic colitis: A literature review

Therapeutic benefits of budesonide in gastroenterology

Contact Info

Product

Resources

About